AUTO 2 NG
Alternative Names: AUTO2-Next Generation; AUTO2-NGLatest Information Update: 28 Jun 2022
At a glance
- Originator University College London
- Developer Autolus
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Multiple myeloma
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for preclinical development in Multiple-myeloma in United Kingdom (Parenteral, Infusion)
- 29 Jan 2019 Preclinical trials in Multiple myeloma in United Kingdom (Parenteral)